AstraZeneca sues DRL on patent Industry-The Economic Times — July 24, 2018 comments off Copies of the drug can be manufactured only after all the patents covering it expire, AstraZeneca’s counsel argued in court on Tuesday.
Copies of the drug can be manufactured only after all the patents covering it expire, AstraZeneca’s counsel argued in court on Tuesday.